home / stock / lyel / lyel news

LYEL News and Press, Lyell Immunopharma Inc. From 12/01/22

Stock Information
Company Name: Lyell Immunopharma Inc.
Stock Symbol: LYEL
Market: NASDAQ
Website: lyell.com
Menu
LYEL LYEL Quote LYEL Short LYEL News LYEL Articles LYEL Message Board
Get LYEL Alerts

News, Short Squeeze, Breakout and More Instantly...
LYEL - Lyell Immunopharma to Participate in BofA Securities Biotech Conference

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team w...
LYEL - Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior management ...

LYEL - Lyell Immunopharma reports Q3 results

Lyell Immunopharma press release ( NASDAQ: LYEL ): Q3 net loss of $43.7M. For further details see: Lyell Immunopharma reports Q3 results

LYEL - Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results

Investigational New Drug (IND) application clearance of LYL845 advances second wholly owned product candidate into clinical development Cash, cash equivalents and marketable securities of $750.7 million as of September 30, 2022; extends funding into 2026 and supports advancement ...
LYEL - Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T - Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a c...

LYEL - Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that members of its senior management ...

LYEL - Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845

Lyell Immunopharma ( NASDAQ: LYEL ) on Thursday said the U.S. FDA had cleared its investigational new drug application to start a phase 1 trial for its experimental cancer therapy LYL845. LYEL stock +4.1% to $8.42 after hours. LYL485 is a tumor infiltrating lymphocyte ...
LYEL - Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

Autologous TIL therapy enhanced with Lyell’s Epi-R™ reprogramming technology designed to create polyclonal T cell populations with properties of durable stemness and improved function Phase 1 trial to initially enroll patients with relapsed and/or refractory metastatic...

LYEL - Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Five poster presentations to include preclinical data describing new T-cell reprogramming technology being incorporated in LYL119, Lyell’s next product candidate SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinic...

LYEL - Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Rahsaan W. Thompson has joined the exe...
Previous 10 Next 10